VANCOUVER, Jan. 5, 2018 /CNW/ – PUF Ventures Inc. (“PUF” or the “Company“) (CSE: PUF) (Frankfurt: PU3) (OTCPK: PUFXF), an advanced Access to Cannabis for Medical Purposes Regulations (“ACMPR”) license applicant, is pleased to announce the Australian government intends to expunge the export ban on cannabis products in February 2018 and allow the export of cannabis products worldwide. The Australian federal government has ambitions for Australia to become the largest producer of medicinal cannabis products in the world.
“We would like to be, potentially, the world’s number one medicinal cannabis supplier,” Greg Hunt, Australia’s Health Minister said in a statement. “By helping the domestic manufacturers to expand, this in turn helps to ensure an ongoing supply of cannabis products here in Australia.”
“We are very encouraged by the support the government of Australia is providing domestic producers like Solaris Nutraceuticals,” said Derek Ivany, President and CEO of PUF Ventures. “We expect significant value to be generated from our partnership in Solaris’ proposed 1.2 million square-foot green house facility in northern New South Wales, which when complete will be the largest production facility in Australia. Australia has a small population and we expect the export of cannabis products to grow beyond current domestic sales of medicinal cannabis.”
About Solaris Nutraceuticals Inc.
Solaris Nutraceuticals is an innovative medical technology company headquartered in Sydney, Australia. It has submitted applications and plans with Australia’s Office of Drug Control to build a 1.2 million square-foot greenhouse facility with cannabis production space and a medical research center in the Northern Rivers Region of New South Wales, Australia. Solaris’ corporate mission is to deliver environmentally friendly, sun grown medicinal grade cannabis and to develop medicines and treatments for pain management and other medical conditions. The company’s focus is on innovations that promote, support and deliver improvements in the quality, consistency and cost of medicines to our clients. For more information, visit www.solarisnutraceuticals.com
About PUF Ventures Inc.
PUF Ventures Inc. is a growth oriented and diversified company focused on the international cannabis industry. It has ownership in several cannabis companies: AAA Heidelberg, Solaris Nutraceuticals Pty Ltd., Weed Points Loyalty Inc., and Natures Hemp Corp., and is actively pursuing other opportunities within the industry. PUF has an option to purchase 100% of AAA Heidelberg Inc., a private Ontario company and advanced applicant for an ACMPR license. Currently, AAA Heidelberg has not received a license from Health Canada. PUF is publicly traded under the following symbols: CSE: PUF, Frankfurt: PU3 and OTCPK: PUFXF. For more information please visit: www.puf.ca.
ON BEHALF OF THE BOARD OF DIRECTORS
Derek Ivany President & CEO
No stock exchange or securities regulatory authority has reviewed or accepted responsibility for the adequacy or accuracy of this release.
Some of the statements contained in this release are forward-looking statements, such as estimates and statements that describe the Issuer’s future plans, objectives or goals, including words to the effect that the Issuer or management expects a stated condition or result to occur. Since forward-looking statements address future events and conditions, by their very nature, they involve inherent risks and uncertainties.
SOURCE PUF Ventures
For further information: PUF Ventures Inc., E: firstname.lastname@example.org, T: (800) 783-6056